In cases of NF2-mutant skull base meningiomas refractory to surgery and radiation, currently, there is no effective chemotherapy; however, PIK3CA, SMO and AKT1 represent promising future therapeutic targets [146,147]. This evidence concerns the gene NF2 and skull base meningioma.